NEW YORK (GenomeWeb News) – ExonHit Therapeutics today announced a reorganization of its business that includes the formation of two new business units: the Molecular Diagnostics and Genomic Services Unit and the Therapeutics Unit.
According to the Paris-based firm, the new company structure has been set up to “realize the value of the company’s intellectual property portfolio.” ExonHit sells the SpliceArray family of microarrays for diagnostic applications and is developing a therapeutic pipeline focused on neurodegenerative diseases and cancer.
The firm has SpliceArray marketing partnerships with Agilent and Affymetrix, and it also has an alliance with bioMérieux to develop predictive blood-based cancer diagnostics.
Under the new company structure, John Jaskowiak will be head of the Molecular Diagnostics and Genomic Services Unit, while Matt Pando will head the Therapeutics Unit.
In addition, ExonHit has recruited new managers: Anders Ingvarsson as vice president of marketing of molecular diagnostics and James Douglas as vice president of corporate strategy and projects. Ingvarsson joins the firm from Sangtec Molecular Diagnostics, where he served as executive vice president, prior to that firm’s acquisition by Cepheid last year.
Douglas previously served as senior vice president of sales and marketing for Epigenomics. Before that, he was vice president of sales and marketing for Biosite, where he was responsible for the launch of that firm’s BNP cardiovascular diagnostic. He also has held marketing positions with Gen-Probe, Centocor, Sanofi Diagnostics Pasteur, and Abbott Laboratories.
ExonHit this year intends to launch whole-genome microarrays for rats and mice and organize its infrastructure to focus on commercializing its first blood-based diagnostic for Alzheimer’s disease.